Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $197.8152W HIGH $485.36
Volume
1.44 M
Value Traded
305.53 M
Short % Float
5.78%
Days to Cover
6.5
-2.41%Week
-10.85%1 Month
-18.23%3 Month
-26.21%6 Month
+110.45%5 Year
+4,776.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
30.46 B
EPS (TTM)
6.04
P/E Ratio
37.70
Ent. Value
27.24 B
Total Shares
133.74 M
Float Shares
133.38 M
Insiders
0.32%
Institutions
100.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ALNY Catalyst Timeline
Dated clinical, regulatory and corporate events for Alnylam Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alnylam Pharmaceuticals, Inc.
817Total events
21Upcoming
307Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutbrezosiranClinical Data
Positive initial Phase 1b data for brezosiran (ALN-HTT02) showing 60-64% mean CSF mHTT reduction at month 3
Huntington's diseasesource ↗
◆Oral PresentationVutrisiranApprovedPresentation
Cardiac Presentation and Treatment Response by Sex in Patients with Transthyretin Amyloidosis
ATTRsource ↗
▲Oral PresentationVutrisiranApprovedPresentation
Alnylam presents new data on AMVUTTRA at ESC Congress 2026
Transthyretin-Amyloidose (ATTR)source ↗
▲Oral PresentationVutrisiranApprovedPresentation
Late-breaking oral presentation of HELIOS-B prespecified subgroup analysis by baseline tafamidis use at ESC Congress 2026
ATTR-CMsource ↗
▲Poster PresentationVutrisiranApprovedPresentation
Pooled analysis across four Phase 3 studies of vutrisiran and patisiran presented at ESC Congress 2026
ATTR-CMsource ↗
▲Oral PresentationZilebesiranPresentation
Oral presentation of KARDIA-3 subgroup analysis at ESC Congress 2026
uncontrolled hypertensionsource ↗
▲PublicationVutrisiranApprovedPresentation
HELIOS-B subgroup analysis simultaneously published in Journal of the American College of Cardiology
ATTR-CMsource ↗
▲Poster PresentationZilebesiranPresentation
New subgroup analysis from KARDIA-3 Phase 2 study of zilebesiran presented at ESC Congress 2026
uncontrolled hypertensionsource ↗
▲Subgroup AnalysisVutrisiranApprovedClinical Data
Post hoc HELIOS-B analysis shows 25% less decline in intrinsic capacity and 52% reduction in risk of decline with vutrisiran
ATTR-CMsource ↗
▲Safety Data UpdateVutrisiranApprovedClinical Data
Post hoc HELIOS-B safety analysis shows fewer adverse events with vutrisiran versus placebo across populations
ATTR-CMsource ↗
▲Pooled AnalysisVutrisiranApprovedClinical Data
Pooled analysis of 1,402 patients shows consistent treatment effects of RNAi-powered TTR silencing across sexes
ATTR-CM and hATTR-PNsource ↗
▲Subgroup AnalysisZilebesiranClinical Data
KARDIA-3 post hoc subgroup analysis shows greater SBP reductions with zilebesiran in patients on background diuretic
uncontrolled hypertensionsource ↗
●RWE DataClinical Data
Real-world evidence shows higher extra-cardiac burden in ATTR-CM patients versus matched controls
ATTR-CMsource ↗
◆Oral PresentationPresentation
Amylo'ExTTRa: Exploring Extra-Cardiac Manifestations in Patients with ATTR-CM Using a French National Health Data System
ATTR-CMsource ↗
●Quarterly UpdateCorporate
Alnylam reports Q2 2026 financial results and recent period progress
●Oral PresentationPresentation
Alnylam highlights neuroscience progress at AAIC 2026
neurological diseasessource ↗
▲Partnership / LicenseCorporate
Komodo expands strategic partnership with Alnylam to scale AI-powered intelligence platform
▲Partnership / LicenseCorporate
GENESIS Pharma expands strategic commercial collaboration with Alnylam to Scandinavian countries
▲Partnership / LicenseCorporate
GENESIS Pharma expands strategic commercial partnership with Alnylam to Nordic region
▲Partnership / LicenseCorporate
Alnylam and Inceptive form strategic AI collaboration to accelerate RNAi therapeutic discovery
▲Oral PresentationVutrisiranApprovedPresentation
Neue Datenanalysen zu Vutrisiran bei ATTR-CM auf Heart Failure 2026 präsentiert
ATTR-CMsource ↗
▲Oral PresentationVutrisiranApprovedPresentation
Pooled analysis of over 25,000 patient-years of safety data for TTR-silencing RNAi therapies presented
ATTR-CMsource ↗
●Trial InitiationVutrisiranApprovedTrial
DemonsTTRate study design presented; expected to enroll >2,000 patients with up to 5 years follow-up
ATTR-CMsource ↗
◆Oral PresentationVutrisiranApprovedPresentation
Treatment with Transthyretin-Lowering RNA Interference Therapeutics is Not Associated with Ocular or Other Clinical Events Due to Vitamin A Reduction: Pooled Analysis of Vutrisiran and Patisiran Data
ATTR-CMsource ↗
◆Oral PresentationVutrisiranApprovedPresentation
Design and Rationale of DemonsTTRate: A Global, Long-Term Observational Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
ATTR-CMsource ↗
◆Oral PresentationVutrisiranApprovedPresentation
Presentatie nieuwe analyses op Heart Failure 2026
ATTR-CMsource ↗
▲Enrollment UpdateNucresiranTrial
Enrollment in TRITON-CM proceeding faster than anticipated; target expanded to ~1,750 patients
ATTR-CMsource ↗
▲Oral PresentationVutrisiranApprovedPresentation
New analyses from HELIOS-B presented at ACC Annual Scientific Session
ATTR-CMsource ↗
▲Partnership / LicenseCorporate
Entered research collaboration with Tenaya Therapeutics for cardiovascular targets
cardiovascular diseasessource ↗
▲Oral PresentationZilebesiranPresentation
Additional Phase 2 results for zilebesiran presented at ACC
hypertensionsource ↗
▲Trial InitiationALN-2232Trial
Initiated Phase 1 trial of ALN-2232 targeting ACVR1C for obesity
obesity and weight managementsource ↗
●NDA SubmissioncemdisiranFiledRegulatory Filing
Regeneron submitted NDA to FDA for cemdisiran in gMG
generalized myasthenia gravissource ↗
▲Product LaunchVutrisiranApprovedPost-Market
One year since U.S. launch of AMVUTTRA for ATTR-CM
ATTR-CMsource ↗
▲Oral PresentationVutrisiranApprovedPresentation
New data presented at ACC.26 for vutrisiran in ATTR-CM
ATTR-CMsource ↗
▲Oral PresentationZilebesiranPresentation
New data presented at ACC.26 for zilebesiran in hypertension
Hypertensionsource ↗
▲Partnership / LicenseCorporate
Strategic collaboration with Viz.ai to advance ATTR-CM care
ATTR-CMsource ↗
◆R&D DayPresentation
Investor webinar marking one-year anniversary of AMVUTTRA approval in ATTR-CM
◆Oral PresentationPresentation
Alnylam presentation at TD Cowen 46th Annual Health Care Conference
▲Other Regulator MilestoneVutrisiranApprovedEx-US Regulatory
Positive recommendation from Canada's Drug Agency (CDA) for public reimbursement of AMVUTTRA for ATTR-CM
cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosissource ↗
◆Oral PresentationPresentation
Management presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Enrollment CompleteMivelsiranTrial
Completed enrollment in cAPPricorn-1 Phase 2 trial in CAA
cerebral amyloid angiopathysource ↗
Past FDA Catalysts and PDUFA Decisions
How ALNY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Mivelsiran | Phase 1 interim results | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
14
Drugs Scored
rNPV / MCap
Top Drug
Top 4%
Mid Cap(rank 27 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Amvuttra | |||
| GIVLAARI | |||
| OXLUMO | |||
| ONPATTRO |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALN-4324 Small moleculeNCT06845202 | Type 2 Diabetes Mellitus (T2DM) | Phase 2 | ACTIVE NOT_RECRUITING | 129 | Aug 31, 2027 | ||||||
| Nucresiran RNA therapyNCT07223203 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | Phase 3 | RECRUITING | 125 | Jun 12, 2031 | ||||||
| Nucresiran RNA therapyNCT07052903 | Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | RECRUITING | 1,750 | Nov 30, 2032 | ||||||
| Zilebesiran RNA therapyNCT07181109 | High Risk Cardiovascular Disease | Phase 3 | RECRUITING | 11,000 | Sep 23, 2030 | ||||||
| ALN-2232 Small moleculeNCT07463846 | Obesity | Phase 1 | RECRUITING | 156 | Apr 28, 2028 | ||||||
| ALN-6222 Small moleculeNCT07624071 | Obesity | Phase 1 | RECRUITING | 88 | Dec 14, 2027 | ||||||
| Mivelsiran RNA therapyNCT07636811 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | Phase 2 | RECRUITING | 58 | Jul 30, 2031 | ||||||
| ALN-APP RNA therapyNCT06393712 | Cerebral Amyloid Angiopathy | Phase 2 | ACTIVE NOT_RECRUITING | 210 | Dec 14, 2029 | ||||||
| ALN-APP RNA therapyNCT05231785 | Early-Onset Alzheimer Disease | Phase 1 | RECRUITING | 60 | Jan 11, 2029 | ||||||
| ALN-AGT01 RVR Small moleculeNCT07553442 | Hypertension | Phase 2 | RECRUITING | 93 | Oct 1, 2028 | ||||||
| ALN-6400 Small moleculeNCT07575308 | Von Willebrand Disease (VWD) | Phase 2 | RECRUITING | 24 | Nov 29, 2028 | ||||||
| ALN-6400 Small moleculeNCT06659640 | Hereditary Hemorrhagic Telangiectasia | Phase 1 | ACTIVE NOT_RECRUITING | 89 | Jun 22, 2028 | ||||||
| ALN-5288 Small moleculeNCT07214727 | Alzheimer's Disease | Phase 1 | RECRUITING | 50 | Mar 6, 2030 | ||||||
| ALN-4285 Small moleculeNCT07295717 | Undisclosed | Phase 1 | RECRUITING | 76 | Mar 23, 2027 | ||||||
| ALN-4915 Small moleculeNCT07535606 | Undisclosed | Phase 1 | ACTIVE NOT_RECRUITING | 36 | Jul 31, 2027 | ||||||
| ALN-BCAT Small moleculeNCT06600321 | Advanced Hepatocellular Carcinoma | Phase 1 | RECRUITING | 158 | Oct 31, 2027 | ||||||
| ALN-HTT02 Small moleculeNCT06585449 | Huntington's Disease | Phase 1 | RECRUITING | 66 | Jul 5, 2028 | ||||||
| Vutrisiran RNA therapyMarketedNCT04153149 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | ACTIVE NOT_RECRUITING | 1,355 | Dec 2, 2026 | ||||||
| Zilebesiran RNA therapyCompletedNCT06272487 | High Cardiovascular Risk | Phase 2 | COMPLETED | 375 | Dec 1, 2025 | ||||||
| ALN-AGT01 RNA therapyCompletedNCT03934307 | Hypertension | Phase 2 | COMPLETED | 518 | Jan 4, 2023 | ||||||
| Zilebesiran RNA therapyCompletedNCT06423352 | Mild to Moderate Hypertension | Phase 1 | COMPLETED | 36 | Jul 17, 2025 | ||||||
| Indapamide Small moleculeCompletedNCT05103332 | Hypertension | Phase 2 | COMPLETED | 663 | Sep 13, 2024 | ||||||
| patisiran RNA therapyMarketedNCT03759379 | Amyloidosis, Hereditary | Phase 3 | COMPLETED | 164 | Nov 5, 2025 | ||||||
| patisiran RNA therapyMarketedNCT03862807 | Amyloidosis, Familial | Phase 3 | COMPLETED | 24 | Oct 20, 2020 | ||||||
| patisiran RNA therapyMarketedNCT01617967 | TTR-mediated Amyloidosis | Phase 3 | COMPLETED | 254 | Jan 1, 2014 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALNY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| brezosiran | Huntington's disease | Phase 1b | 2026-10-23 | significant huntingtin loweringRead More | Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SUPRAN BRYANOfficer (EVP, CLO and Secretary) | Sell | -1,758 12,807 held | $226.88 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALNY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 3.6 % | 248.35 M | 825.00 K | 65% ( 325.00 K) |
ALNY Institutional Ownership Trends
ALNY Short Interest
Shares sold short, counted twice a month.
5.78%
Short % of Float
of tradable shares sold short
7.7M
Shares Sold Short
+7.2% vs prior count
6.5 High
Days to Cover
trading days of normal volume to buy every short share back
1.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALNY ranks across every disease it competes in
Competitive Position is a premium feature
See how ALNY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALNY News
ALNY▲ +1.6%today
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease
Alnylam Pharmaceuticals announced positive initial Phase 1b data for brezosiran, showing a mean reduction of mutant huntingtin protein by 60-64% at month 3. The study demonstrated individual reductions of up to 83% with a favorable safety profile. A pivotal study is planned for 2027, pending regulatory alignment.
Read more →ALNYAlnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
Alnylam Pharmaceuticals will report its third quarter 2026 financial results on October 29, 2026. The management will discuss the results and future expectations during a conference call at 8:30 am ET. A live audio webcast will be available on their website, with an archived version accessible shortly after the event.
Read more →ALNYAMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Alnylam Pharmaceuticals has launched the AMVUTTRA® (vutrisiran) ‘Play by Play’ initiative, aimed at educating the public about transthyretin-mediated amyloidosis (ATTR-CM). This initiative features stories from former professional athletes and their care teams to highlight the often-missed signs of the condition. The goal is to promote early recognition of symptoms for better patient care.
Read more →ALNY▲ +8.7%on this news
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam Pharmaceuticals has announced that its management will present company overviews at two upcoming investor conferences. The Wells Fargo 21st Annual Healthcare Conference is scheduled for September 8, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference will take place on September 14, 2026. Both events will feature live audio webcasts.
Read more →ALNYAlnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Alnylam Pharmaceuticals presented new data at the ESC Congress 2026, highlighting the effectiveness of RNAi-powered silencing in treating cardiovascular diseases. The results strengthen the clinical profile of AMVUTTRA® (vutrisiran) in various patient populations and treatment settings for transthyretin amyloidosis (ATTR). This reinforces the drug's potential across different manifestations of the disease.
Read more →ALNYAlnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
Alnylam Pharmaceuticals will present new clinical and real-world data at the ESC Congress 2026. The data will focus on their transthyretin-mediated amyloidosis (ATTR) and hypertension programs. This presentation aims to reinforce the efficacy of their RNAi-powered therapies. The congress is scheduled for August 28-31, 2026, in Munich, Germany.
Read more →ALNY▼ -28.3%on this news
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals reported significant financial results for Q2 2026, highlighting a historic achievement of over $1 billion in quarterly product revenues. The company emphasized its ongoing advancements in the RNAi therapeutics sector and expressed optimism about future growth. This performance marks a pivotal moment in Alnylam's business trajectory.
Read more →ALNYAlnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
Alnylam Pharmaceuticals will report its second quarter 2026 financial results on July 30, 2026, before market opening. The management team will discuss these results and provide future expectations during a conference call scheduled for 8:30 am ET on the same day. This event highlights the company's ongoing commitment to transparency and stakeholder engagement.
Read more →ALNYAlnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
Alnylam Pharmaceuticals presented significant advancements in its neuroscience programs at the AAIC 2026. The company emphasized the potential of RNA interference (RNAi) therapeutics to meet the needs of patients suffering from neurological diseases. Notably, the investigational therapeutic Mivelsiran targets amyloid precursor protein, which could have implications for treatment.
Read more →ALNYKomodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
Komodo has expanded its strategic partnership with Alnylam Pharmaceuticals to enhance its AI-powered intelligence platform. This collaboration aims to leverage advanced analytics to improve healthcare outcomes. The details of the expansion and its implications for both companies were not specified in the article.
Read more →ALNYAlnylam to Host Tenth “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals is set to host the tenth installment of its 'RNAi Roundtable' webcast series. This event aims to engage stakeholders in discussions about RNA interference technology and its applications. Further details about the webcast, including speakers and topics, have not been provided in the article.
Read more →ALNYGENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
GENESIS Pharma has expanded its strategic partnership with Alnylam Pharmaceuticals to enhance the commercialization of RNAi therapeutics in the Nordic region. This collaboration aims to leverage both companies' strengths to improve patient access to innovative treatments. The partnership reflects a commitment to advancing RNAi technology in new markets.
Read more →ALNYAlnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam Pharmaceuticals has announced a strategic collaboration with Inceptive to leverage artificial intelligence in the discovery of RNA interference (RNAi) therapeutics. This partnership is expected to enhance the efficiency and effectiveness of developing new RNAi-based treatments. The collaboration highlights the growing trend of integrating AI in biopharmaceutical research.
Read more →ALNYAlnylam Issues 2025 Corporate Responsibility Report
Alnylam Pharmaceuticals has released its 2025 Corporate Responsibility Report. The report outlines the company's commitment to sustainability and ethical practices. However, specific details regarding the content of the report are not provided in the article.
Read more →ALNYNew Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
The article discusses new data analyses presented at Heart Failure 2026 regarding Vutrisiran as a first-line treatment for ATTR-CM patients. The findings suggest that Vutrisiran offers robust and consistent clinical benefits across diverse patient populations, including those with a high disease burden. However, specific details about the data or outcomes are not provided.
Read more →ALNYAlnylam to Webcast Presentations at Upcoming Investor Conferences
Alnylam Pharmaceuticals will present company overviews at two upcoming investor conferences: the BofA Securities Healthcare Conference on May 13, 2026, and the Goldman Sachs Annual Healthcare Conference on June 9, 2026. Live audio webcasts of the presentations will be available on the company's website, with replays accessible within 48 hours post-event.
Read more →ALNYAlnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Alnylam Pharmaceuticals is set to present new analyses at the Heart Failure 2026 conference. The focus will be on the consistent clinical profile of Vutrisiran in treating ATTR-CM. This presentation aims to highlight the drug's effectiveness and reliability in managing heart failure associated with this condition.
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals reported strong financial results for Q1 2026, achieving over $1 billion in product revenues. The company is advancing its RNAi therapeutics pipeline, including three Phase 3 trials and a new Phase 1 study for obesity. Notably, the TRITON-CM study of nucresiran is expanding enrollment due to faster-than-expected patient recruitment.
Read more →ALNYAlnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
Alnylam Pharmaceuticals has announced a conference call to discuss its financial results for the first quarter of 2026. The call will provide insights into the company's performance and future outlook. Details regarding the timing and access to the webcast will be provided closer to the date.
Read more →ALNYNew Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
The article mentions new data presented at ACC.26 regarding Vutrisiran's benefits in treating ATTR-CM and highlights Zilebesiran's potential for hypertension management. However, specific details about the data or outcomes are not provided.
Read more →About Alnylam Pharmaceuticals, Inc.
Headquarters675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142
Founded2002
BIOPHARMAWATCH ELITE PLUS
Trade the next ALNY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime